Japan’s Sawai Pharmaceutical Co., Ltd. is aiming to capture a 20% share of its domestic generics market and achieve ¥400bn ($3.65bn) in group revenues by its 2030 financial year, according to a new long-term business plan, which also includes ambitions to almost double sales in its nascent US operations in that timeframe.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?